Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M

Biofrontera Inc.

Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.
Full-year 2025 revenue $41.7M, up 12% YoY; net loss narrowed to $10.5M from $17.7M.
Gross margin improved to 82.4% in Q4 (from 58.0%) due to new earnout structure after asset purchase from Biofrontera AG.
Adjusted EBITDA was $4.9M in Q4 vs. -$1.4M; full-year Adjusted EBITDA -$10.6M vs. -$15.3M.
Pipeline: PDUFA date for sBCC September 2026; positive Phase 3 AK results; Phase 2b acne data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.